<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004220</url>
  </required_header>
  <id_info>
    <org_study_id>202103 P07</org_study_id>
    <nct_id>NCT05004220</nct_id>
  </id_info>
  <brief_title>Effects of Plasmapheresis on Aging Biomarkers</brief_title>
  <official_title>Studie Vlivu darování krevní Plazmy - Plasmapheresis. Study of the Plasma Donation Effect - Plasmapheresis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longevitytech.fund a.s.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clock Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AGECURVE LIMITED</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of plasmapheresis (repeated plasma&#xD;
      withdrawals) on selected health indicators (hematological, biochemical, immunological and&#xD;
      indicators of biological age) of plasma donors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Significant change of biological age according to epigenetic clock after 8 plasmaphereses</measure>
    <time_frame>Through study completion, an average of 8 months</time_frame>
    <description>Significant change of the epigenetic age of the plasma donors after 8 cycles of plasmapheresis conducted or a slower increase of the biological age throughout the study than the increase of the chronological age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant change of biological age according to epigenetic clock after 8 plasmaphereses</measure>
    <time_frame>Through study completion, an average of 8 months</time_frame>
    <description>Significant change of the epigenetic age of the plasma donors after 4 cycles of plasmapheresis conducted or a slower increase of the biological age throughout the study than the increase of the chronological age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant change of the proteomic profile after 8 plasmaphereses</measure>
    <time_frame>Through study completion, an average of 8 months</time_frame>
    <description>Proteomic analysis showing signs of a rejuvenated proteostasis in the plasma donors after 8 cycles of plasmapheresis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant change of the proteomic profile after 4 plasmaphereses</measure>
    <time_frame>Through study completion, an average of 8 months</time_frame>
    <description>Proteomic analysis showing signs of a rejuvenated proteostasis in the plasma donors after 8 cycles of plasmapheresis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant change of the biological age according to a blood biochemistry clock after 8 plasmaphereses</measure>
    <time_frame>Through study completion, an average of 8 months</time_frame>
    <description>Blood biochemistry clock showing phenotype of a younger individual in the plasma donors after 8 cycles of plasmapheresis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant change of the biological age according to a blood biochemistry clock after 4 plasmaphereses</measure>
    <time_frame>Through study completion, an average of 8 months</time_frame>
    <description>Blood biochemistry clock showing phenotype of a younger individual in the plasma donors after 8 cycles of plasmapheresis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Aging</condition>
  <condition>Plasmapheresis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Group 1 consists of first time donors undergoing all 8 tracked plasmaphereses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Group 2 consists of first time donors undergoing only last 4 plasmaphereses, serving as control for the first 4 donations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasmapheresis</intervention_name>
    <description>Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        41 donors are welcomed to begin with the study. The participants are divided into 2 groups&#xD;
        (Group 1 = therapeutic, Group 2 = half control) using stratified randomization, major&#xD;
        criteria being chronological age and BMI, minor criteria being illness/medication, smoking,&#xD;
        COVID in past 3 months, covid vaccination.&#xD;
&#xD;
        Group 1 consists of 28 participants (14 female, 14 male). Group 2 consists of 13&#xD;
        participants (7 female, 6 male). We suppose that the number of participants will decline&#xD;
        during each phase of the study, approx. 10% before it even starts, 10% in the middle, 10%&#xD;
        in the end. The goal is to have more than 30 participants finishing the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Generally healthy volunteer subjects age 40 - 60&#xD;
&#xD;
          2. 50:50 man and woman&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects excluded from plasma donation protocols (serious illness, infection, etc)&#xD;
&#xD;
          2. Subjects undergoing stronger anti-aging interventions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charles University, Medical Faculty in Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Pavel Borsky</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Plasmapeheresis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

